2024
Inter-Rater Reliability for the Amputation Endpoint in the National Vascular Quality Initiative
Smolderen K, Romain G, Scierka L, Cleman J, Rahman M, Siddiqui W, Lau F, Mao J, Akhlaghi N, Higaki A, Fowler X, Carroll M, Telma K, Alvermann T, Baribeau V, Goodney P, Mena-Hurtado C. Inter-Rater Reliability for the Amputation Endpoint in the National Vascular Quality Initiative. JACC Cardiovascular Interventions 2024, 17: 622-631. PMID: 38479964, DOI: 10.1016/j.jcin.2024.01.003.Peer-Reviewed Original ResearchConceptsElectronic health recordsElectronic health record reviewAmputation dataPeripheral arterial diseaseInterrater reliabilityVQI registryAcademic health systemTrained data collectorsNational quality registryInter-rater reliabilityEvaluate interrater reliabilityNational reporting systemHealth recordsQuality registryHealth systemCurrent Procedural Terminology codesInter-raterVascular Quality Initiative registryVascular Quality InitiativeProcedural Terminology codesNational Vascular Quality InitiativeRegistryQuality InitiativeAmputationSpearman's rVariability in guideline-directed medical therapy across sites and operators and long-term mortality and amputation outcomes risk in patients undergoing peripheral vascular interventions
Smolderen K, Romain G, Cleman J, Scierka L, Mena-Hurtado C. Variability in guideline-directed medical therapy across sites and operators and long-term mortality and amputation outcomes risk in patients undergoing peripheral vascular interventions. American Heart Journal 2024, 270: 75-85. PMID: 38307364, DOI: 10.1016/j.ahj.2024.01.008.Peer-Reviewed Original ResearchMedian odds ratioGuideline-directed medical therapy prescriptionGuideline-directed medical therapy ratesPeripheral vascular interventionsGuideline-directed medical therapyIntraclass correlationHealth system levelDecrease hospital readmissionsPatient-level factorsGuideline-directed medical therapy useAssociated with higher riskAngiotensin-converting enzyme inhibitor/angiotensin receptor blockerRisk of deathParametric survival modelsInhibitor/angiotensin receptor blockerProportion of riskHospital readmissionVascular Quality Initiative registryLong-term mortalityOdds ratioReadmission riskVascular interventionsLogistic regressionDose-response relationshipAmputation
2023
Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions
Smolderen K, Romain G, Provance J, Scierka L, Mao J, Goodney P, Henke P, Sedrakyan A, Mena-Hurtado C. Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. JACC Cardiovascular Interventions 2023, 16: 332-343. PMID: 36792257, PMCID: PMC10359106, DOI: 10.1016/j.jcin.2022.09.022.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyPeripheral vascular interventionsMedical therapyVascular interventionsEnzyme inhibitors/angiotensin receptor blockersVascular Quality Initiative registryAngiotensin receptor blockersLong-term mortalityRisk of amputationRisk of mortalityNational quality registryQuality improvement effortsAmputation outcomesAmputation riskMajor amputationAntiplatelet therapyCause mortalityReceptor blockersMean ageVascular careQuality registryObservational studyMortality riskHigh riskAmputation data
2022
Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classification